NAFLD (Nonalcoholic Liver Disease) is the most common cause of chronic liver disease globally. 20% to 30% of people with a NAFLD diagnosis progress to a NASH diagnosis (nonalcoholic steatohepatitis), which can lead to advanced fibrosis, cirrhosis, or liver failure with an estimated lifetime cost of $222B in inpatient care.
Qualitative assessment of hepatic steatosis can be subjective. Conventional methods of ultrasound-based liver fat quantification can be difficult to understand. Ultrasound Derived Fat Fraction (UDFF) on the ACUSON Sequoia is fast, simple and intuitive. UDFF, with a total exam time of less than 1 minute, can classify hepatic steatosis as an index value greater than 5%*, delivering a similar clinical utility as MRI-PDFF1,2.
Download the UDFF white paper to learn how to manage hepatic steatosis through liver fat quantification, to aid in successful clinical assessment.